©2022 Stanford Medicine
Stanford Universities: The Stanford HIV Aging Cohort
Trial ID: NCT01401348
A research study to evaluate the effect of aging and HIV on neurocognitive dysfunction (declining ability to process information), physical frailty and heart disease. HIV-infected participants whose virus is controlled on antiretroviral medications will be studied to determine the rates and risk factors of developing these conditions.
The Stanford HIV Aging Cohort (SHAC)
- Subjects must have an HIV RNA level below the limit of quantification (e.g., <75
copies, <50 copies, or <48 copies/mL, depending on the assay used) for at least 6
months excluding "blips" (e.g., a single measurement between 48-200 copies/mL preceded
and followed by measurements below the limit of quantification) while on
1. Completed treatment for any acute systemic infection (other than HIV-1) less than four
weeks before study entry.
2. Any active brain infection (except for HIV-1), brain neoplasm, or space-occupying
3. Receipt of immunomodulating medication (e.g., corticosteroids, immunoglobulin, etc.)
within four weeks of study entry.
4. Any active psychiatric illness including schizophrenia, severe depression, or severe
bipolar affective disorder that, in the opinion of the investigator, could confound
the analysis of the neuropsychological test results.
5. Active drug or alcohol abuse that, in the investigator's opinion, could prevent
compliance with study procedures or confound the analysis of study endpoints.
6. Unable to provide informed consent
School of Medicine
300 Pasteur Drive
Stanford, CA 94305